Obstetric and Gynecologic Imaging

What Imaging Is Best for Staging Large or Locally Involved Vulvar Cancer?

·
What Imaging Is Best for Staging Large or Locally Involved Vulvar Cancer?

A 72-year-old woman presents to your gynecologic oncology clinic with a large, ulcerated vulvar mass, biopsy-proven to be squamous cell carcinoma. On examination, the tumor measures approximately 5 cm and appears to extend to the posterior vaginal fourchette and perineal body, with questionable involvement of the anal sphincter. Before you can formulate a treatment plan—be it primary surgery, radiation, or chemoradiation—you need to understand the full extent of the disease. This requires precise anatomical detail of the primary tumor’s local invasion and an assessment of regional lymph nodes. This article details the American College of Radiology (ACR) recommended imaging workflow for this exact scenario. For this presentation, the ACR rates `MRI pelvis without and with IV contrast` as Usually appropriate.

Who Fits This Clinical Scenario for Locally Advanced Vulvar Cancer?

This guidance applies specifically to the initial, pretreatment staging of patients with biopsy-proven vulvar cancer who present with features suggesting locally advanced disease. The key inclusion criteria are:

  • A primary vulvar tumor measuring greater than 4 cm in its largest dimension.
  • A primary vulvar tumor of any size that demonstrates more than minimal clinical involvement of adjacent lower one-third structures, such as the urethra, vagina, or anus.

This workflow is distinct from other clinical situations. It is crucial to differentiate this scenario from:

  • Small, localized tumors: Patients with primary tumors ≤ 4 cm with only superficial stromal invasion may not require cross-sectional imaging for local staging. Their workup is covered in a different ACR variant.
  • Post-treatment surveillance or suspected recurrence: Imaging for a patient with a history of treated vulvar cancer who now has symptoms concerning for recurrence follows a separate diagnostic algorithm. This article is strictly for the initial, pretreatment workup.

Applying this guidance correctly ensures that patients with a higher risk of deep pelvic extension and nodal metastasis receive the most appropriate imaging to inform complex treatment decisions from the outset.

What Diagnoses Are You Working Up in This Scenario?

While the primary diagnosis of vulvar cancer is already established by biopsy, the purpose of imaging in this scenario is staging—determining the anatomic extent of the disease. The key questions you are trying to answer directly inform the FIGO (International Federation of Gynecology and Obstetrics) stage and subsequent treatment plan.

Primary Tumor Extent (T-stage): The most critical question is the depth and path of local invasion. Imaging aims to delineate the tumor’s relationship with the pelvic floor muscles, urethra, bladder neck, vagina, anus, and rectum. Clear visualization of these structures is essential to determine surgical resectability and plan radiation fields.

Regional Nodal Metastasis (N-stage): Vulvar cancer first spreads to the inguinal and femoral lymph nodes, followed by the external and internal iliac (pelvic) nodes. Cross-sectional imaging is used to identify suspicious nodes based on size, morphology, and enhancement characteristics. The presence and location of nodal disease is a major prognostic factor and dictates the need for lymph node dissection and/or radiation.

Distant Metastasis (M-stage): While pelvic imaging is focused on local and regional disease, it can sometimes identify metastatic spread to the pelvic bones or unexpected sites within the scanned area. For larger tumors, the risk of distant disease is higher, and more extensive imaging may be warranted.

Why Is MRI of the Pelvis Without and With IV Contrast the Recommended Study?

For assessing a large or locally invasive vulvar tumor, `MRI pelvis without and with IV contrast` is rated Usually appropriate by the ACR because of its superior soft-tissue contrast resolution. This modality excels at defining the anatomic planes between the tumor and adjacent pelvic organs, which is the central clinical question in this scenario.

MRI provides exquisite detail of the tumor’s infiltration into the vaginal wall, urethral sphincter, anal sphincter complex, and levator ani muscles. T2-weighted sequences are particularly valuable for this assessment. The addition of IV contrast helps characterize the tumor, assess for necrosis, and improve the detection of metastatic lymph nodes, which often demonstrate avid enhancement. A key advantage of MRI is its lack of ionizing radiation (0 mSv), an important consideration in a patient who will likely undergo radiation therapy as part of their treatment.

Other imaging studies are also rated for this scenario, but often serve different or secondary roles:

  • FDG-PET/CT skull base to mid-thigh: This study is also rated Usually appropriate. It is highly sensitive for detecting nodal and distant metastatic disease. It is often used as a complementary study or in cases where distant disease is highly suspected. However, it provides less fine anatomical detail of the primary tumor’s local invasion compared to a dedicated pelvic MRI.
  • CT chest abdomen pelvis with IV contrast: Also rated Usually appropriate, this is an excellent tool for assessing distant metastatic disease in the lungs, liver, and distant nodes. However, its soft-tissue resolution in the pelvis is inferior to MRI for delineating the primary tumor’s extent. It exposes the patient to significant ionizing radiation (☢☢☢☢ 10-30 mSv).
  • US-guided fine needle aspiration biopsy groin: This is rated May be appropriate (Disagreement). If imaging identifies a suspicious inguinal lymph node, ultrasound can be used to guide a biopsy for definitive pathologic confirmation, which can be critical for treatment planning.

What’s Next After MRI of the Pelvis? Downstream Workflow

The results of the pelvic MRI are a critical input for the multidisciplinary tumor board and will directly guide the next steps in management. The workflow typically branches based on the findings:

  • If the MRI shows resectable disease: If the tumor is confined without invasion into the bladder, rectum, or pelvic sidewall, and nodal disease appears limited, the patient may be a candidate for primary surgical resection (e.g., radical vulvectomy and inguinofemoral lymphadenectomy).
  • If the MRI shows unresectable or borderline resectable disease: If there is clear invasion of the rectum, bladder, or pelvic bone, or bulky, fixed nodal disease, the patient will likely be referred for primary chemoradiation. The MRI images are essential for the radiation oncologist to accurately contour the tumor and target volumes.
  • If the MRI shows suspicious lymph nodes: If nodes are identified that are suspicious for metastasis, the next step may be a biopsy to confirm. An ultrasound-guided fine-needle aspiration (FNA) of an inguinal node is often performed. Pathologic confirmation of nodal disease can upstage the patient and solidify the need for adjuvant or primary radiation.
  • If the MRI is indeterminate or suggests distant disease: If findings are equivocal, or if there is concern for disease beyond the pelvis, an `FDG-PET/CT` is an excellent problem-solving tool to clarify nodal status and survey for distant metastases.

Pitfalls to Avoid (and When to Get Help)

In staging locally advanced vulvar cancer, several imaging pitfalls can impact management. First, failing to administer IV contrast during the MRI can severely limit the assessment of tumor vascularity and the conspicuity of metastatic lymph nodes. Second, recent biopsy can cause significant inflammation and edema, which can be mistaken for tumor on imaging, potentially overestimating its size; noting the date of biopsy is crucial. Third, relying solely on lymph node size as a criterion for metastasis is unreliable, as small nodes can harbor cancer and large nodes can be reactive. Morphological features like rounded shape and loss of the fatty hilum are more specific signs on MRI. If the imaging findings are discordant with the clinical examination, discussion with the reporting radiologist and the multidisciplinary team is essential before finalizing a treatment plan.

Related ACR Topics and Tools

This article focuses on a single, complex scenario. For a comprehensive overview of imaging across all presentations of this condition, please consult the parent topic guide. For additional resources on imaging selection, technique, and safety, the following tools are available.

Frequently Asked Questions

Why is MRI preferred over CT for staging a large vulvar tumor?

MRI is preferred because its superior soft-tissue resolution provides much clearer detail of the primary tumor’s invasion into adjacent structures like the vagina, urethra, and anal sphincter. This is the most critical information needed for local staging and treatment planning. While CT is also rated ‘Usually appropriate,’ it is less precise for this specific task but better for evaluating distant disease in the chest and abdomen.

Is FDG-PET/CT a good first-choice imaging study in this scenario?

FDG-PET/CT is also rated ‘Usually appropriate’ and is an excellent single study for assessing both nodal and distant metastatic disease. However, for the primary goal of defining the local T-stage—the precise extent of tumor invasion into nearby pelvic organs—a dedicated pelvic MRI is generally superior. Often, MRI is performed for local staging and PET/CT is added if there is high suspicion of metastatic disease or if nodal status is equivocal on MRI.

What imaging should be ordered if my patient has a contraindication to MRI?

If a patient has a contraindication to MRI (e.g., a non-compatible pacemaker or severe claustrophobia), ‘CT chest abdomen pelvis with IV contrast’ is an appropriate alternative. While it offers less soft-tissue detail for the primary tumor, it provides a comprehensive assessment of pelvic and inguinal nodes as well as distant metastatic sites. The radiologist should be made aware that the CT is being performed as an alternative to MRI for local staging so they can optimize the protocol.

Does this patient also need a dedicated chest CT?

The need for chest imaging depends on the overall staging plan. If you order an ‘FDG-PET/CT skull base to mid-thigh,’ the CT portion of that scan provides adequate imaging of the chest. If you opt for an ‘MRI pelvis’ for local staging, ordering a separate ‘CT chest with IV contrast’ is reasonable to complete staging and evaluate for pulmonary metastases, given the higher risk associated with locally advanced disease.

How would the imaging recommendation change if the tumor was only 3 cm and confined to the vulva?

That presentation falls under a different ACR scenario (‘Primary tumor is less than or equal to 4 cm with greater than 1 mm stromal invasion’). For smaller tumors without clinical involvement of adjacent structures, cross-sectional imaging like MRI or CT is often not required for initial staging, as the risk of deep pelvic invasion or distant metastasis is much lower. The workup in that case focuses more on clinical assessment and sentinel lymph node biopsy.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026